Products & Services


Nanopore sequencing offers advantages in all areas of research. Our offering includes DNA sequencing, as well as RNA and gene expression analysis and future technology for analysing proteins.

Learn about applications
View all Applications
News Explore
Contact Get started

Oxford Nanopore announces £109.5M ($144.5M) in investment and share sales

Thu 2nd January 2020

2 January 2020, Oxford, UK:  Oxford Nanopore Technologies has raised £29.3M ($38.6M) in new capital and additionally facilitated the sale of £80.2M ($105.9) in secondary shares, resulting in total gross proceeds of £109.5M ($144.5M). 
These funds have been raised internationally and include both new investors and existing shareholders, from the US, Europe and Asia/Pacific.
This brings the total primary investment in Oxford Nanopore to ~£480M to date. 
Further information on Oxford Nanopore’s fundraising will be made available in due course.

The Company made substantial progress in 2019; from scaling up to population-scale sequencing with PromethION, to accurate, rapid testing in cancer and infectious disease.; Read 19 highlights of 2019.


USD amounts assume exchange rate of 1.32 at 31st December 2019.

Open a chat to talk to our sales team